

1 **Erythrocyte Osmotic Fragility as A Diagnostic Marker in Glaucoma: A Comprehensive**  
2 **Analysis Using LASSO Regression**

3 Jialiang Yang<sup>1,\*</sup>, Fang Yang<sup>1,\*</sup>, Junming Gu<sup>2</sup>, Yilian Cheng<sup>3</sup>, Qian Luo<sup>3</sup>, Fang Hao<sup>1</sup>, Bo Gong<sup>1,4</sup>,  
4 Houbin Zhang<sup>1,4,#</sup>

5 <sup>1</sup>The Key Laboratory for Human Disease Gene Study of Sichuan Province and Institute of  
6 Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science  
7 and Technology of China, Chengdu, Sichuan, China;

8 <sup>2</sup>Medical Information Center, Sichuan Provincial People's Hospital, school of medicine,  
9 University of Electronic Science and Technology of China

10 <sup>3</sup>Department of Ophthalmology, Sichuan Provincial People's Hospital, University of  
11 Electronic Science and Technology of China, Chengdu, Sichuan, China.

12 <sup>4</sup>Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences  
13 (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People's  
14 Hospital, Chengdu, Sichuan, China.

15 \*These authors contributed to this work equally.

16 #Correspondence should be addressed to: Houbin Zhang, Ph.D, The Sichuan Provincial Key  
17 Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University  
18 of Electronic Science and Technology of China,  
19 32 The First Ring Road West 2, Chengdu, Sichuan, 610072, China.

20 Email: [houbin\\_zhang@yahoo.com](mailto:houbin_zhang@yahoo.com)

21 Phone: 86-28-87393375; Fax: 86-28-87393596

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43 **Abstract**

44

45 **Objective:** This study investigates the potential of blood biomarkers in the early diagnosis of  
46 glaucoma, focusing on erythrocyte osmotic fragility (EOF) as a novel indicator. We used  
47 Least Absolute Shrinkage and Selection Operator (LASSO) regression to evaluate EOF's  
48 predictive utility for glaucoma diagnosis.

49 **Methods:** We included 195 confirmed glaucoma patients and an equal number of age- and  
50 sex-matched healthy controls. Blood samples were analyzed for various parameters, including  
51 white blood cell count, neutrophil count, red blood cell (RBC) count, and EOF. Key  
52 differential markers were identified, and a predictive model was constructed using LASSO  
53 regression models.

54 **Results:** LASSO regression analysis identified HCT, NEUT, LYMPH, MCV, MCHC, and  
55 EOF as critical blood biomarkers discriminating glaucoma patients from healthy controls.  
56 Incorporating EOF into the model significantly enhanced its predictive performance, with  
57 EOF showing a positive correlation with the likelihood of glaucoma.

58 **Conclusions:** EOF is a promising predictive biomarker for glaucoma. Combining EOF with  
59 other blood biomarkers significantly improves the accuracy of glaucoma diagnosis.

60

61

62

63

64

65 **Introduction**

66

67 Glaucoma is the leading cause of irreversible vision loss worldwide, characterized by  
68 complex and multifactorial pathophysiology involving both known and potential risk factors  
69 [1-4]. Although glaucoma is traditionally linked to elevated intraocular pressure (IOP),  
70 clinical evidence suggests that approximately 30% of glaucoma patients exhibiting normal  
71 IOP (<21 mmHg) still suffer from irreversible optic nerve damage [5]. This observation  
72 implies the presence of additional critical pathogenic factors that underlie  
73 pathophysiology of glaucoma beyond IOP [6].

74

75 Recent advances in molecular biology have highlighted the potential role of blood biomarkers  
76 in the onset and progression of glaucoma [7-11]. Blood biomarkers not only provide a  
77 systemic reflection of physiological and pathological status but also reveal specific  
78 pathological alterations in glaucoma patients, such as oxidative stress and inflammation [8,  
79 12-15]. These alterations may play a significant role in the pathophysiology of glaucoma.

80

81 Oxidative stress and inflammation are central elements in the pathogenesis of glaucoma [10,  
82 12, 15-17]. Oxidative stress elevates reactive oxygen species (ROS) levels, directly damaging  
83 erythrocyte membranes by inducing lipid peroxidation and reducing membrane stability [15,  
84 18-22]. Inflammation exacerbates this damage by releasing inflammatory mediators (e.g.,  
85 TNF- $\alpha$ , IL-1 $\beta$ ), further compromising erythrocyte membrane integrity. As erythrocytes are  
86 primarily responsible for oxygen transport, increased erythrocyte osmotic fragility (EOF)

87 affects oxygen transport mainly by causing cell membrane rupture, shape changes, and  
88 reduced elasticity [23-28]. This makes red blood cells (RBCs) more prone to rupture in the  
89 microcirculation, decreasing the number of functional RBCs. Additionally, membrane  
90 fragility impacts membrane protein function and disrupts hemoglobin's ability to bind and  
91 release oxygen, thereby reducing overall oxygen transport efficiency. [23-28]. Therefore, EOF  
92 may reflect membrane stability and indicate ongoing pathological processes in glaucoma,  
93 such as chronic oxidative stress and inflammation.

94

95 Therefore, we hypothesize that elevated EOF is associated with glaucoma. Based on this  
96 hypothesis, we propose that EOF, as a novel biomarker, can effectively differentiate glaucoma  
97 patients from healthy controls, thereby improving the accuracy of early glaucoma diagnosis

98

99 This study aims to systematically evaluate the diagnostic potential of EOF and other blood  
100 biomarkers in glaucoma using the Least Absolute Shrinkage and Selection Operator (LASSO)  
101 [29-32] regression model. By constructing an efficient diagnostic model, we seek to provide a  
102 robust theoretical foundation and practical guidance for early glaucoma screening and precise  
103 diagnosis.

104

## 105 **Materials and Methods**

### 106 **1. Study Population**

107 This study included 195 confirmed glaucoma patients and 195 age- and sex-matched healthy  
108 controls. All participants were provided informed consent, and the study was conducted

109 following the Declaration of Helsinki and approved by the ethics committees of Sichuan  
110 Provincial People's Hospital.

111

112 Participants in the glaucoma group met the International Glaucoma Association's diagnostic  
113 criteria, including IOP  $\geq$ 21 mmHg, structural optic nerve changes (e.g., optic atrophy,  
114 increased cup-to-disc ratio), and visual field defects. Patients with other severe ocular  
115 diseases, recent ocular trauma, or significant systemic conditions were excluded.

116

117 The control group was selected based on comprehensive ophthalmological examinations  
118 confirming the absence of glaucoma or other major ocular diseases, with age and sex matched  
119 to the glaucoma group. Exclusion criteria included systemic diseases affecting ocular health,  
120 recent ocular surgery, and medications influencing IOP.

121

## 122 **2. Blood Sample Collection and Analysis**

123 Fasting peripheral blood samples were collected in the morning using EDTA tubes (BD, USA)  
124 by trained technicians. Samples were stored at 4°C and analyzed within two hours. Blood  
125 samples were analyzed using an automated hematology analyzer (Mindray, China) to  
126 measure parameters such as white blood cell count (WBC), neutrophils (NEUT), lymphocytes  
127 (LYMPH), monocytes (MONO), eosinophils (EOS), basophils (BASO), RBC count,  
128 hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular  
129 hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell  
130 distribution width-standard deviation (RDW-SD), and platelet count (PLT).

131 **3. EOF test (EOFT)**

132 EOF was measured using a standardized osmotic fragility test [33], which assesses  
133 erythrocyte membrane stability by determining the critical osmotic pressure at which  
134 erythrocytes rupture. Briefly, 50  $\mu$ L of blood was added to different concentrations of  
135 hypotonic saline solutions containing 0.7%, 0.65%, 0.6%, 0.55%, 0.5%, 0.45%, 0.4%, 0.35%,  
136 0.3%, or 0.25% NaCl (Sigma, USA) and gently mixed. The solutions were left at room  
137 temperature (25°C) for 2 hours. Afterward, the red blood cells' resistance to the hypotonic  
138 solutions was examined by assessing hemolysis. The concentration of the hypotonic saline  
139 solution at which hemolysis first began indicated the minimum resistance of the red blood  
140 cells in the blood, while complete hemolysis indicated the maximum resistance. Lower  
141 resistance to hypotonic saline solutions signifies greater fragility of the red blood cells,  
142 whereas higher resistance indicates less fragility. The range from maximum resistance to  
143 minimum resistance is referred to as the fragility range.

144

145 **4. Giemsa staining**

146 Giemsa staining is a classic staining method used to observe the morphology of blood cells  
147 [34]. Blood was used to prepare a thin smear and allowed for air dry. The smear was fixed  
148 with methanol for 5 minutes. The A Giemsa staining kit (Yeasen, China) was used to stain the  
149 smear follow the manufacturer's instruction. The stained smear was imaged under a  
150 microscope.

151

152 **5. Statistical Analysis**

153 LASSO regression (Least Absolute Shrinkage and Selection Operator) is a linear regression  
154 method that introduces an L1 regularization term to handle high-dimensional data and  
155 multicollinearity issues. It can shrink the coefficients of unimportant features to zero, thereby  
156 achieving feature selection and model sparsity. LASSO regression not only improves the  
157 predictive performance of models but also enhances their interpretability, making it an  
158 effective tool for analyzing high-dimensional datasets, with widespread applications across  
159 various fields.

160

161 LASSO regression introduces an L1 regularization term in the regression model to handle  
162 multicollinearity effectively and automatically select the most useful features for prediction  
163 [29-32]. All features were standardized, and cross-validation was used to select the optimal  
164 regularization parameter  $\lambda$ . After fitting the LASSO model on the training set, features with  
165 non-zero coefficients were extracted to construct the final predictive model. Model  
166 performance was evaluated through independent validation sets. Sensitivity analyses were  
167 conducted to verify the model's applicability and robustness across different subgroups (e.g.,  
168 age, sex) (**Figure 1A**).

169

170 The data with a normal distribution were expressed as mean  $\pm$  SD. The independent *t*-test was  
171 used to compare the means between the two groups. The statistical significance level was set  
172 to  $\alpha = 0.05$ . All statistical analyses were two-sided tests and performed by using GraphPad  
173 Prism 10.0 (GraphPad Software, USA).

174



175 **Results**

176 **1. LASSO regression analysis suggests inflammation in glaucoma patients and abnormal**

177 **RBC status**

178 To identify the features that distinguish glaucoma patients from healthy controls, we used  
179 LASSO regression analysis for feature selection. **Table 1** presents the basic information about  
180 the control and glaucoma groups.

181

182 We determined the optimal regularization parameter ( $\lambda$ ) of the LASSO model, which was  
183 0.0355 (**Figures 1B,C**). The results of the LASSO regression analysis (**Figure 1D**) showed  
184 that the coefficients for Neutrophil count (NEUT, coefficient: 0.45), Neutrophil percentage  
185 (NEUT%, coefficient: 0.38), RBC Distribution Width (RDW-SD, coefficient: 0.27), Mean  
186 Corpuscular Hemoglobin Concentration (MCHC, coefficient: -0.19), and Platelet count (PLT)  
187 were non-zero, indicating that these biomarkers are significant for distinguishing glaucoma  
188 patients from healthy controls(all p-values for the coefficients were less than 0.05).

189

190 Specifically, the positive coefficients for Neutrophil count (NEUT), Neutrophil percentage  
191 (NEUT%), and RBC Distribution Width (RDW-SD) suggest that increases in these indicators  
192 are positively correlated with the occurrence of glaucoma. Neutrophil count (NEUT) and  
193 Neutrophil percentage (NEUT%) are commonly used to reflect systemic inflammation[35-38],  
194 and growing evidence indicates that the pathogenesis of glaucoma is closely associated with  
195 chronic inflammation. RBC Distribution Width (RDW-SD), which is related to RBC  
196 heterogeneity, indicates that the RBC status in glaucoma patients may differ from that of

197 healthy individuals.

198

199 We further evaluated the reliability and performance of the model using a confusion matrix

200 (**Figure 1E**). The LASSO regression model demonstrated excellent classification ability in

201 distinguishing glaucoma patients from healthy controls, showing a high overall accuracy

202 (87.5%), sensitivity (82.4%), and specificity (91.6%). These results suggest that the LASSO

203 model, based on blood biomarkers, can effectively identify glaucoma patients and has

204 potential clinical application value.

205 Despite the model's strong performance, there were still some false positives and false

206 negatives (**Figure 1E**). This indicates that further optimization of the model may be necessary,

207 particularly through validation in larger sample sizes across different patient populations, to

208 ensure the model's robustness and broad applicability.

209

## 210 **2. EOF is increased in glaucoma patients**

211 The LASSO analysis result suggested that glaucoma was associated with chronic

212 inflammation and that their RBC membranes might be more fragile. To evaluate the fragility

213 and stability of RBC membranes, the EOF test (EOFT) was performed. This test evaluates the

214 fragility of red blood cell membranes by measuring the extent of cell rupture in different

215 concentrations of saline solutions (**Figure 2A**). We analyzed blood samples from 113

216 glaucoma patients and their healthy controls., The results showed that the EOF (NaCl

217 concentration for minimum resistance) levels in glaucoma patients were significantly higher

218 than those in the control group (**Figures 2B, C**,  $p < 0.001$ ). Additionally, staining of red blood

219 cells revealed that the proportion of RBCs with abnormal morphologies was significantly  
220 increased in glaucoma patients (**Figures 2D, E**).

221

222 Further individual analysis showed that the EOF in two patients (arbitrarily designated as  
223 patients A and B, respectively) was higher than in the control (**Figure 2F**). In addition, the  
224 RBCs of another patient A displayed complete hemolysis in 0.55% NaCl, whereas the RBCs  
225 of patient B only partially hemolyzed in 0.55% NaCl, indicating greater resistance to osmotic  
226 stress for patient B (**Figure 2F**). Optical coherence tomography (OCT) examination showed  
227 that patient B had better optic nerve fiber thickness and cup-to-disc ratio than patient A  
228 (**Figures 2G, H**), suggesting a correlation between EOF and the pathological severity of  
229 glaucoma.

230

231 Based on these findings, we propose EOF as a potential novel diagnostic marker for glaucoma.  
232 This discovery not only provides a new tool for the early diagnosis of glaucoma, but also  
233 offers new insights into the pathophysiological mechanisms of the disease. However, further  
234 studies are needed to validate the direct correlation between EOF and optic nerve function  
235 and to evaluate its practical application in clinical settings.

236

### 237 **3. EOF can be used as a potential marker for glaucoma prediction**

238 Next, we test whether EOF can be used as a potential marker for the prediction of primary  
239 open-angle glaucoma (POAG), the predominant form of glaucoma. We recruited a family  
240 with early-onset glaucoma, and performed a longitudinal study (the pedigree information is

241 available upon request). The family consisted of seven members, designed F1-F7. Family  
242 members F1, F3 and F4 were diagnosed with POAG, whereas other members were normal.  
243 EOFT revealed that all family members with glaucoma had significantly elevated EOF  
244 relative to normal family members (**Figure 3A, B**).

245

246 Interestingly, family member F4 (aged 16-20), who is the sibling of F1, showed significantly  
247 elevated EOF despite no obvious signs of glaucoma during the initial OCT examination. The  
248 follow-up examination a year later showed that family member F4 exhibited signs of  
249 glaucoma, such as increased cup-to-disc ratio, thinning of the retinal nerve fiber layer, and  
250 visual field defects, compared to the normal family member F5, whose RBCs exhibited  
251 normal EOF (**Figure 3C, D, E**). This finding suggests that EOF may have a significant  
252 potential for predicting glaucoma or early glaucoma diagnosis before the detection by routine  
253 clinical examinations, such as OCT. However, further research is needed to validate the  
254 potential of EOF as a biomarker for glaucoma prediction and monitoring.

255

#### 256 **4. EOF's role in AI-based analysis**

257 To further validate EOF's role in glaucoma diagnosis, we re-analyzed an independent set of  
258 glaucoma patients and healthy controls, incorporating EOF into the LASSO model. Category  
259 mean analysis showed that the differences in multiple blood markers were more pronounced  
260 in the glaucoma group, particularly EOF, which was significantly higher in the glaucoma  
261 group than in the control group (**Table 2**).

262

263 In the LASSO regression analysis, the optimal  $\lambda$  value was 0.01760928, and the final model  
264 identified HCT, NEUT, LYMPH, MCV, MCHC, and EOFT as key blood markers. The  
265 coefficient table (**Table 3**) showed that EOF had the most significant positive coefficient in  
266 the glaucoma group ( $p < 0.01$ ), further validating its critical role in glaucoma diagnosis.

267

268 The confusion matrix result of the LASSO regression model showed high classification  
269 accuracy in predicting glaucoma and healthy controls, with low false positive and false  
270 negative rates (**Figure 4A**). Thus, EOF, as an emerging novel biomarker, significantly  
271 enhanced the predictive performance of the LASSO regression model.

272

273 Despite the results showing EOF's promising potential in glaucoma diagnosis, it is important  
274 to note that the standardization of EOF measurement remains challenging. Additionally, the  
275 relatively small sample size in this study highlights the need for further research to validate  
276 these findings in larger cohorts and to explore the broader clinical application of EOFT.

277

## 278 **5. Prediction model construction and Validation of the model construction**

279

### 280 **5.1 Construction of the glaucoma prediction model**

281 Based on LASSO regression analyses, we identified six key features: HCT, NEUT, LYMPH,  
282 MCV, MCHC, and EOF. These features were integrated into the final glaucoma prediction  
283 model, with the predictive formula as follows:

284  $\text{Logit}(p) = -38.1157 + (-0.1079 \times \text{HCT}) + (0.5502 \times \text{NEUT}) + (-0.0474 \times \text{LYMPH}) + (-0.0135 \times \text{MCV}$   
285  $) + (0.0762 \times \text{MCHC}) + (42.9581 \times \text{EOF})$

286 Using the logistic regression model, the probability  $p$  can be calculated by the following  
287 formula:

288 
$$p = \frac{1}{1 + \exp(-\text{Logit}(p))}$$

289 By substituting the feature values HCT, NEUT, LYMPH, MCV, MCHC, and EOF into the  
290 formula, the corresponding probability value  $p$  can be calculated.

291 All regression coefficients were statistically significant ( $p < 0.05$ ), indicating the importance  
292 of these variables in the model.

### 293 5.2. Model performance evaluation

294 The model demonstrated excellent discriminatory ability on the test set, with an area under  
295 the ROC curve (AUC) of 0.98, indicating near-perfect discrimination between glaucoma  
296 patients and healthy controls (**Figure 4B**). The heatmap in **Figure 4C** shows the predicted  
297 probabilities of glaucoma compared to the actual group classifications. The predicted  
298 probabilities for each sample are shown in **Figure 4D**. The purple dots representing glaucoma  
299 patients are mostly concentrated in the high probability range, whereas the green dots  
300 representing healthy controls are predominantly distributed in the low probability range. This  
301 further demonstrates the model's high discriminatory ability. **Table 4** summarizes the overall  
302 performance of the model, including accuracy, sensitivity, specificity, and AUC.

### 303 5.3. Actual prediction results

304 **Table 5** presents the actual blood parameters and corresponding predicted probabilities for a  
305 subset of glaucoma patients and healthy controls. The model successfully predicted the  
306 majority of glaucoma cases, validating its potential for clinical application. Notably, the  
307 predicted probabilities closely matched the actual disease status, further confirming the  
308 model's accuracy and reliability.

#### 309 5.4. External validation results

310 To validate the external applicability of the model, we conducted external validation on three  
311 independent datasets. The model achieved AUC values of 0.96, 0.94, and 0.95 on these  
312 datasets, respectively, indicating good generalizability across different patient populations  
313 (**Table 6**).

314 The glaucoma prediction model developed in this study demonstrated exceptional  
315 discriminatory power and good generalizability across multiple datasets. The high AUC  
316 values indicate that the model is highly accurate and reliable for clinical application,  
317 providing an effective tool for early screening and intervention in glaucoma.

318

#### 319 **Discussion**

320 For the first time, this study systematically introduces EOF as a biomarker in glaucoma  
321 diagnosis, and comprehensively evaluates the differences in multiple blood biomarkers  
322 between glaucoma patients and healthy controls using the LASSO regression model. The  
323 results indicate that NEUT, NEUT%, MCHC, EOF, and other blood markers have significant

324 discriminatory power in glaucoma diagnosis, with EOF standing out as a key potential  
325 parameter in glaucoma screening.

326 This study demonstrated that EOF was positively correlated with glaucoma severity in,  
327 indicating that EOF could serve as a diagnostic marker for glaucoma as well as a tool for  
328 monitoring disease progression. The elevation of EOF may reflect ongoing oxidative stress  
329 and inflammation in glaucoma patients, consistent with previous reports and confirming the  
330 critical role of oxidative stress in the pathogenesis of glaucoma [39, 40]. Compared to  
331 traditional IOP monitoring, EOFT offers advantages such as simplicity, and low cost, making  
332 it particularly suitable for large-scale screening in high-risk populations. These findings  
333 provide a new perspective for clinical application, suggesting that EOFT could be  
334 incorporated into routine health checks for early detection and intervention in glaucoma.

335

336 Additionally, this study demonstrates that the degree of EOF elevation in glaucoma patients is  
337 correlated with disease severity. This suggests that EOFT can serve as both a diagnostic  
338 marker and a disease progression indicator, providing clinicians with a new tool for patient  
339 management and monitoring [26, 41]. By incorporating EOF into the diagnostic model, the  
340 accuracy of the LASSO regression model in predicting glaucoma is significantly enhanced.

341 The model's high sensitivity and specificity further highlight its potential in glaucoma  
342 screening. As more data are accumulated and models are continuously optimized, blood  
343 biomarker-based glaucoma prediction models are expected to become a routine tool in clinical  
344 practice, providing essential support for the early diagnosis and intervention of glaucoma [7, 9,  
345 19, 42].



346

347 Although significant results have been achieved, this study has certain limitations. First, the  
348 relatively small sample size may affect the model's generalizability. In the future, a larger  
349 sample size can be carried out to further verify the model before it can be used in the clinical  
350 application. Second, while EOFT demonstrated significant diagnostic value in this study, its  
351 measurement techniques need further optimization to ensure consistency and standardization  
352 across different laboratories. Moreover, this study primarily utilized LASSO regression for  
353 analysis. Future studies should consider incorporating more complex machine learning  
354 algorithms, such as random forests and support vector machines, to improve the model's  
355 predictive accuracy and robustness.

356

357 Future research could focus on the following areas: Firstly, further exploration of the causal  
358 relationship between increased EOF and glaucoma progression, particularly through long-  
359 term follow-up studies, to clarify the dynamic association between EOFT changes and disease  
360 progression. Secondly, the development and validation of a more simplified EOFT  
361 measurement method to facilitate its use in clinical practice. Finally, as sample sizes increase,  
362 future studies could consider integrating EOFT with multi-omics data, such as genomics and  
363 proteomics, to build a multi-dimensional and multi-indicator glaucoma diagnostic platform,  
364 enhancing the accuracy and effectiveness of early diagnosis and disease monitoring for  
365 glaucoma.

366

367 **Funding support**

368 This research project was supported by the National Natural Science Foundation of China  
369 (82371059 (H.Z.), 82371060 (B.G.)), the Department of Science and Technology of Sichuan  
370 Province, China (2023JDZH0002 (H.Z.)), and Sichuan Provincial People's Hospital  
371 (30320230095 (J.Y.), 30420220062 (J.Y.)), Natural Science Foundation of Sichuan Province  
372 (2024NSFC1719 (J.Y.),30420230353 (J.Y.)).

373

#### 374 **Authors contributions**

375 J.Y. and F.Y. designed, performed experiments and analyzed the data. J.G, Y.C, H.F. and Q.L.  
376 recruited the participants, performed the ophthalmic examination. B.G. analyzed the data. H.Z.  
377 conceived the project, designed the experiments, and supervised the project. J.Y wrote the  
378 first draft of the manuscript. H.Z. edited the manuscript.

379

#### 380 **Declaration of competing interest**

381 The authors declare no competing interests.

382

#### 383 **Data Availability Statement**

384 All data produced in the present study are available upon reasonable request to the authors.

385

#### 386 **References**

387

388 1. Jayaram, H., et al., *Glaucoma: now and beyond*. Lancet, 2023. **402**(10414): p. 1788-

389 1801.

- 390 2. Stein, J.D., A.P. Khawaja, and J.S. Weizer, *Glaucoma in Adults-Screening, Diagnosis,*  
391 *and Management: A Review.* *Jama*, 2021. **325**(2): p. 164-174.
- 392 3. Voelker, R., *What Is Glaucoma?* *Jama*, 2023. **330**(16): p. 1594.
- 393 4. Singh, L.N., et al., *Mitochondrial DNA Variation and Disease Susceptibility in*  
394 *Primary Open-Angle Glaucoma.* *Invest Ophthalmol Vis Sci*, 2018. **59**(11): p. 4598-  
395 4602.
- 396 5. Fox, A.R. and J.H. Fingert, *Familial normal tension glaucoma genetics.* *Prog Retin*  
397 *Eye Res*, 2023. **96**: p. 101191.
- 398 6. Hamel, A.R., et al., *Integrating genetic regulation and single-cell expression with*  
399 *GWAS prioritizes causal genes and cell types for glaucoma.* *Nat Commun*, 2024.  
400 **15**(1): p. 396.
- 401 7. Beutgen, V.M., et al., *Autoantibody Biomarker Discovery in Primary Open Angle*  
402 *Glaucoma Using Serological Proteome Analysis (SERPA).* *Front Immunol*, 2019. **10**:  
403 p. 381.
- 404 8. Harris, A., et al., *The effects of antioxidants on ocular blood flow in patients with*  
405 *glaucoma.* *Acta Ophthalmol*, 2018. **96**(2): p. e237-e241.
- 406 9. Hubens, W.H.G., et al., *Blood biomarkers for assessment of mitochondrial*  
407 *dysfunction: An expert review.* *Mitochondrion*, 2022. **62**: p. 187-204.
- 408 10. Vergroesen, J.E., et al., *The inflammatory potential of diet is associated with the risk*  
409 *of age-related eye diseases.* *Clin Nutr*, 2023. **42**(12): p. 2404-2413.
- 410 11. Petriti, B., et al., *Peripheral blood mononuclear cell respiratory function is*  
411 *associated with progressive glaucomatous vision loss.* *Nat Med*, 2024. **30**(8): p. 2362-

- 412 2370.
- 413 12. Lei, Y., et al., *Oxidative stress impact on barrier function of porcine angular aqueous*  
414 *plexus cell monolayers*. Invest Ophthalmol Vis Sci, 2013. **54**(7): p. 4827-35.
- 415 13. Pinazo-Durán, M.D., et al., *Biochemical-molecular-genetic biomarkers in the tear*  
416 *film, aqueous humor, and blood of primary open-angle glaucoma patients*. Front Med  
417 (Lausanne), 2023. **10**: p. 1157773.
- 418 14. Stuart, K.V., et al., *The Association of Urinary Sodium Excretion with Glaucoma and*  
419 *Related Traits in a Large United Kingdom Population*. Ophthalmol Glaucoma, 2024.
- 420 15. Yildirim, O., et al., *Role of oxidative stress enzymes in open-angle glaucoma*. Eye  
421 (Lond), 2005. **19**(5): p. 580-3.
- 422 16. Mokbel, T.H., et al., *Erythropoietin and soluble CD44 levels in patients with primary*  
423 *open-angle glaucoma*. Clin Exp Ophthalmol, 2010. **38**(6): p. 560-5.
- 424 17. Tabak, S., S. Schreiber-Avissar, and E. Beit-Yannai, *Crosstalk between MicroRNA*  
425 *and Oxidative Stress in Primary Open-Angle Glaucoma*. Int J Mol Sci, 2021. **22**(5).
- 426 18. Mohandas, N. and P.G. Gallagher, *Red cell membrane: past, present, and future*.  
427 Blood, 2008. **112**(10): p. 3939-48.
- 428 19. Feilchenfeld, Z., Y.H. Yücel, and N. Gupta, *Oxidative injury to blood vessels and glia*  
429 *of the pre-laminar optic nerve head in human glaucoma*. Exp Eye Res, 2008. **87**(5): p.  
430 409-14.
- 431 20. Murphy, S.C., et al., *Lipid rafts and malaria parasite infection of erythrocytes*. Mol  
432 Membr Biol, 2006. **23**(1): p. 81-8.
- 433 21. Kuhn, V., et al., *Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric*

- 434            *Oxide Metabolism, Anemia*. *Antioxidants & Redox Signaling*, 2017. **26**(13): p. 718-
- 435            742.
- 436    22.    Massacesi, L., E. Galliera, and M.M.C. Romanelli, *Erythrocytes as markers of*
- 437            *oxidative stress related pathologies*. *Mechanisms of Ageing and Development*, 2020.
- 438            **191**: p. 111333.
- 439    23.    Behling-Kelly, E. and R. Collins-Cronkright, *Increases in beta-lipoproteins in*
- 440            *hyperlipidemic and dyslipidemic dogs are associated with increased erythrocyte*
- 441            *osmotic fragility*. *Vet Clin Pathol*, 2014. **43**(3): p. 405-15.
- 442    24.    Abou-Seif, M.A., A. Rabia, and M. Nasr, *Antioxidant status, erythrocyte membrane*
- 443            *lipid peroxidation and osmotic fragility in malignant lymphoma patients*. *Clin Chem*
- 444            *Lab Med*, 2000. **38**(8): p. 737-42.
- 445    25.    Yücel, R., et al., *Erythrocyte osmotic fragility and lipid peroxidation in experimental*
- 446            *hyperthyroidism*. *Endocrine*, 2009. **36**(3): p. 498-502.
- 447    26.    Nemkov, T., et al., *Regulation of kynurenine metabolism by blood donor genetics and*
- 448            *biology impacts red cell hemolysis in vitro and in vivo*. *Blood*, 2024. **143**(5): p. 456-
- 449            472.
- 450    27.    Tu, H., et al., *Low Red Blood Cell Vitamin C Concentrations Induce Red Blood Cell*
- 451            *Fragility: A Link to Diabetes Via Glucose, Glucose Transporters, and*
- 452            *Dehydroascorbic Acid*. *EBioMedicine*, 2015. **2**(11): p. 1735-50.
- 453    28.    Yoong, W.C., S.M. Tuck, and A.E. Michael, *Binding of ovarian steroids to*
- 454            *erythrocytes in patients with sickle cell disease; effects on cell sickling and osmotic*
- 455            *fragility*. *J Steroid Biochem Mol Biol*, 2003. **84**(1): p. 71-8.

- 456 29. Bai, J., et al., *Prognostic factors for polyp recurrence in chronic rhinosinusitis with*  
457 *nasal polyps*. J Allergy Clin Immunol, 2022. **150**(2): p. 352-361.e7.
- 458 30. Tang, G., et al., *Evaluation and analysis of incidence and risk factors of lower*  
459 *extremity venous thrombosis after urologic surgeries: A prospective two-center cohort*  
460 *study using LASSO-logistic regression*. Int J Surg, 2021. **89**: p. 105948.
- 461 31. Wu, J., et al., *Normalization weighted combination scores re-evaluate TNM staging of*  
462 *gastric cancer: a retrospective cohort study based on a multicenter database*. Int J  
463 Surg, 2024. **110**(1): p. 11-22.
- 464 32. Yang, Y., et al., *Prediction models of surgical site infection after gastrointestinal*  
465 *surgery: a nationwide prospective cohort study*. Int J Surg, 2024. **110**(1): p. 119-129.
- 466 33. Dobrynina, L.A., et al., *The Predictive Value of Salt Sensitivity and Osmotic Fragility*  
467 *in the Development of Cerebral Small Vessel Disease*. Int J Mol Sci, 2020. **21**(6).
- 468 34. Best, L.M., et al., *Non-invasive diagnostic tests for Helicobacter pylori infection*.  
469 Cochrane Database Syst Rev, 2018. **3**(3): p. Cd012080.
- 470 35. Chou, M.L., et al., *Blood-brain crosstalk: the roles of neutrophils, platelets, and*  
471 *neutrophil extracellular traps in neuropathologies*. Trends Neurosci, 2023. **46**(9): p.  
472 764-779.
- 473 36. Crossley, J.L., et al., *Itaconate-producing neutrophils regulate local and systemic*  
474 *inflammation following trauma*. JCI Insight, 2023. **8**(20).
- 475 37. Xu, B., et al., *Is systemic inflammation a missing link between cardiometabolic index*  
476 *with mortality? Evidence from a large population-based study*. Cardiovasc Diabetol,  
477 2024. **23**(1): p. 212.

- 478 38. Zhao, E., et al., *The systemic immune-inflammation index was non-linear associated*  
479 *with all-cause mortality in individuals with nonalcoholic fatty liver disease.* *Ann Med*,  
480 2023. **55**(1): p. 2197652.
- 481 39. Młynarczyk, M., et al., *Diet, Oxidative Stress, and Blood Serum Nutrients in Various*  
482 *Types of Glaucoma: A Systematic Review.* *Nutrients*, 2022. **14**(7).
- 483 40. Benoist d'Azy, C., et al., *Oxidative and Anti-Oxidative Stress Markers in Chronic*  
484 *Glaucoma: A Systematic Review and Meta-Analysis.* *PLoS One*, 2016. **11**(12): p.  
485 e0166915.
- 486 41. Fatima, K., et al., *Neomenthol prevents the proliferation of skin cancer cells by*  
487 *restraining tubulin polymerization and hyaluronidase activity.* *J Adv Res*, 2021. **34**: p.  
488 93-107.
- 489 42. Chen, H., et al., *A Case of Glaucoma in Hereditary Spherocytosis.* *J Glaucoma*, 2018.  
490 **27**(12): p. e187-e190.
- 491
- 492
- 493
- 494
- 495
- 496
- 497
- 498
- 499

500

501

502 **Figure Legends**

503 **Figure 1. LASSO regression analysis to identify blood biomarkers between glaucoma**

504 **patients and normal controls. (A)** LASSO model construction flowchart. **(B)** Distribution of

505 regression coefficients. **(C)** Bar chart of key features. **(D)** Model performance evaluation. **(E)**

506 Confusion matrix showing the prediction result for the glaucoma patients and health controls.

507

508 **Figure 2. Higher EOF in glaucoma patients. (A)** Flowchart of EOFT. **(B)** Statistical result

509 showing the average concentration of NaCl at which RBCs started to show hemolysis

510 (minimum resistance). The data are expressed as mean  $\pm$  SEM. \*\*\*\*,  $p < 0.0001$ ; unpaired  $t$ -

511 test. **(C)** Histogram of the concentrations (Conc.) of NaCl of minimum resistance for each

512 glaucoma patient and normal control. **(D)** Representative image showing Giemsa staining of

513 RBCs from glaucoma patients and normal controls. The data are expressed as mean  $\pm$  SEM.

514 \*\*\*\*,  $p < 0.0001$ ; unpaired  $t$ -test. **(E)** Quantification of the Giemsa staining result showing

515 the percentage of abnormal RBCs in glaucoma patients and controls. **(F)** EOFT result for

516 glaucoma patients A and B and normal control. **(G-H)** OCT results of patients A and B. RNFL;

517 retinal nerve fiber layer; TEMP; temporal; SUP, superior; NAS: nasal; INF: inferior; OD:

518 right eye; OS; left eye.

519

520 **Figure 3. EOF as a potential marker for POAG prediction. (A)** Schematic showing the

521 EOFT result from seven members (F1-F7) in this family. **(B)** Distribution of the NaCl



522 concentrations of minimum resistance for members in this family subjected to EOFT test. (C)  
523 Image of the EOFT result for family members F4 and F5. (D) Statistical chart of RNFL  
524 thickness at different areas in the retina for family members F4 and F5. (F) Statistical chart of  
525 parameters of the optic nerve head for family members F4 and F5. RNFL; retinal nerve fiber  
526 layer; TEMP; temporal; SUP, superior; NAS: nasal; INF: inferior; OD: right eye; OS; left eye;  
527 vol: volume.

528

529 **Figure 4. External dataset validation.** (A) Confusion matrix plot after adding the EOFT  
530 result. (B) ROC Curve for the glaucoma prediction model. (C) Heatmap of the predicted  
531 probability of glaucoma. (D) Scatterplot of the predicted probability

532

533

534

535

536

537

538

539

540


541

542

543

544

Figure 1



545

546

547

548

549

550


551

552

553

Figure 2

554




555

556

557

**Figure 3**

558



559

560

561

562

563

564

565

566

567


568

569

570

Figure 4

571



572

573

574

575 **Table 1. Demographic information for control and glaucoma patients**

576

Group	Age (Mean)	Man	Woman	Total
Control	57.05	54	28	82
Glaucoma	56.36	54	28	82

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595 **Table 2. Means for each blood parameter for the second control and glaucoma group**

596

Item	Control (Mean)	Control (SD)	Glaucoma (Mean)	Glaucoma (SD)
RBC	4.8	0.43	4.6	0.53
HCT	45	3.4	42	4.5
MCH	31	1.3	31	1.7
PLT	184	55	194	58
WBC	5.8	1.5	6.7	2
NEUT	3.4	1.1	4.3	1.7
LYMPH	1.8	0.56	1.7	0.6
MONO	0.4	0.15	0.48	0.17
BASO	0.03	0.04	0.04	0.02
HGB	145	12	141	17
MCV	94	3.9	92	4.2
MCHC	325	9.2	332	12
EOF	0.4	0.01	0.48	0.05

597

598

599

600

601

602

603

604

605

606 **Table 3. Table of results of confusion matrix coefficients for the LASSO regression**

607 **model**

608

<b>Variant</b>	<b>Regression coefficient</b>	<b>Standard error</b>	<b>Wald Chi-Square</b>	<b><i>p</i>-value</b>
HCT	-0.1079	0.015	51.65	< 0.001
NEUT	0.5502	0.22	6.27	0.012
LYMPH	-0.0474	0.012	15.52	< 0.001
MCV	-0.0135	0.006	4.53	0.033
MCHC	0.0762	0.033	5.38	0.02
EOFT	42.9581	9.567	20.18	< 0.001

609

610

611

612

613

614

615

616

617

618

619

620



621 **Table 4. Model performance metrics**

622

<b>Metric</b>	<b>Value</b>
Accuracy	95.20%
Sensitivity	92.10%
Specificity	96.30%
AUC	0.98

623

**Table 5. Actual patient data and predicted probabilities**

<b>Patient ID</b>	<b>HCT</b>	<b>NEUT</b>	<b>LYMPH</b>	<b>MCV</b>	<b>MCHC</b>	<b>EOFT</b>	<b>Actual Status</b>	<b>Predicted Probability (%)</b>
1	42.0	2.590	1.290	93.8	338	0.5	Glaucoma	99.08
2	45.5	5.774	1.671	84.9	347	0.4	Glaucoma	92.70
3	42.9	2.351	1.080	92.5	333	0.4	Glaucoma	44.95
4	48.7	2.784	1.408	94.6	349	0.5	Glaucoma	93.89
5	45.0	3.195	1.198	92.6	344	0.5	Glaucoma	95.32
6	47.3	4.015	1.420	94.8	334	0.5	Glaucoma	91.79
7	43.6	6.315	1.381	94.2	351	0.4	Glaucoma	96.22
8	40.3	5.740	1.361	92.0	333	0.5	Glaucoma	98.34
9	43.0	9.649	1.954	92.3	333	0.4	Glaucoma	83.41
10	50.3	3.040	1.890	95.8	348	0.4	Glaucoma	15.31
11	47.8	3.761	2.703	91.9	345	0.4	Glaucoma	22.13
12	45.7	3.211	1.279	84.8	330	0.5	Glaucoma	87.89
13	34.4	6.368	2.261	86.6	328	0.5	Glaucoma	99.11
14	35.9	5.048	1.267	93.7	345	0.4	Glaucoma	68.52
15	39.3	5.147	1.653	98.7	326	0.5	Glaucoma	96.19
16	40.8	5.184	1.539	91.3	343	0.4	Glaucoma	91.20
17	40.4	4.173	1.240	93.7	332	0.5	Glaucoma	95.76
18	42.9	4.777	3.923	91.3	319	0.5	Glaucoma	98.58
19	42.6	3.467	1.948	88.8	336	0.5	Glaucoma	94.42
20	46.0	3.216	2.359	91.3	341	0.5	Glaucoma	93.41
21	42.0	6.545	1.241	89.6	326	0.4	Glaucoma	84.55
22	42.1	3.890	3.132	93.3	335	0.4	Glaucoma	68.45
23	45.0	4.112	1.373	93.2	329	0.5	Glaucoma	98.91

24	40.2	3.096	2.040	88.9	326	0.5	Glaucoma	98.61
25	30.7	4.027	0.919	88.5	342	0.5	Glaucoma	99.28
26	37.6	4.191	2.047	87.6	322	0.5	Glaucoma	93.77
27	35.8	3.483	1.038	98.6	318	0.5	Glaucoma	98.61
28	42.7	2.088	0.651	90.3	333	0.6	Glaucoma	99.79
29	38.2	3.040	1.431	74.0	309	0.5	Glaucoma	96.72
30	40.7	12.634	1.067	91.7	319	0.5	Glaucoma	99.99
31	50.4	3.224	2.043	89.7	312	0.5	Glaucoma	89.63
32	45.0	5.790	3.028	91.8	331	0.6	Glaucoma	99.95
33	47.6	3.849	1.470	99.8	324	0.5	Glaucoma	97.36
34	38.3	4.037	2.248	92.7	326	0.6	Glaucoma	99.92
35	42.0	2.635	1.121	98.1	319	0.5	Glaucoma	96.09
36	44.8	2.360	1.271	95.9	335	0.5	Glaucoma	98.18
37	32.4	3.260	1.342	91.5	321	0.5	Glaucoma	99.19
38	36.2	4.257	0.710	96.5	301	0.5	Glaucoma	96.74
39	40.7	2.469	1.501	97.1	332	0.5	Glaucoma	88.98
40	39.6	8.521	1.647	93.0	321	0.5	Glaucoma	99.14
41	42.5	5.918	1.579	89.7	346	0.6	Glaucoma	99.99
42	43.6	4.997	3.273	90.3	326	0.5	Glaucoma	93.81
43	41.8	2.468	1.490	92.7	337	0.4	Glaucoma	56.53
44	38.1	4.875	1.139	91.1	325	0.5	Glaucoma	96.30
45	46.2	3.183	1.999	92.0	318	0.4	Glaucoma	21.74
46	43.7	3.011	0.980	88.3	330	0.4	Glaucoma	47.68
47	50.6	4.015	1.821	96.0	320	0.4	Glaucoma	23.31
48	47.3	2.698	2.161	91.0	334	0.5	Glaucoma	84.64
49	44.7	3.251	1.569	86.5	358	0.4	Glaucoma	88.70
50	39.1	3.530	1.161	98.2	327	0.5	Glaucoma	99.02

51	45.9	5.880	2.527	92.2	342	0.6	Glaucoma	99.98
52	39.2	4.875	1.809	95.6	324	0.5	Glaucoma	95.12
53	36.2	1.619	0.989	90.0	340	0.5	Glaucoma	99.32
54	46.7	3.516	1.358	96.1	334	0.5	Glaucoma	89.94
55	46.7	6.753	1.338	88.1	334	0.5	Glaucoma	99.80
56	42.6	3.862	1.717	87.7	345	0.4	Glaucoma	83.34
57	46.2	5.258	2.058	93.3	351	0.4	Glaucoma	91.33
58	47.8	4.144	1.870	89.5	324	0.5	Glaucoma	97.95
59	43.4	3.079	2.691	94.6	353	0.5	Glaucoma	97.61
60	35.7	4.468	1.502	92.7	319	0.5	Glaucoma	94.25
61	46.4	4.118	1.192	93.4	325	0.5	Glaucoma	87.13
62	46.9	3.646	1.639	84.4	365	0.4	Glaucoma	93.08
63	35.7	3.424	2.259	89.2	311	0.5	Glaucoma	83.55
64	36.7	3.890	0.860	97.1	332	0.5	Glaucoma	99.59
65	43.2	4.168	1.453	96.2	343	0.5	Glaucoma	99.68
66	40.8	3.742	1.739	89.3	343	0.5	Glaucoma	97.61
67	36.1	4.341	1.228	92.6	327	0.4	Glaucoma	76.14
68	38.5	5.096	0.871	94.6	319	0.4	Glaucoma	66.76
69	46.1	4.503	1.060	93.3	328	0.5	Glaucoma	98.94
70	42.9	3.021	1.202	91.3	343	0.5	Glaucoma	95.63
71	35.3	5.884	1.222	88.9	323	0.5	Glaucoma	99.78
72	53.9	5.764	2.084	86.8	332	0.5	Glaucoma	99.13
73	41.9	3.989	1.381	104.2	325	0.5	Glaucoma	98.69
74	47.4	3.161	2.148	91.9	344	0.4	Glaucoma	16.87
75	46.5	4.836	2.669	91.9	333	0.6	Glaucoma	99.92
76	43.0	5.483	1.523	94.9	316	0.4	Glaucoma	54.02
77	40.5	3.920	1.523	91.2	323	0.4	Glaucoma	11.99

78	38.4	7.204	2.091	93.2	318	0.4	Glaucoma	40.25
79	41.4	5.152	1.533	92.0	326	0.5	Glaucoma	95.69
80	47.3	3.460	1.396	92.2	345	0.5	Glaucoma	95.18
81	41.2	3.800	1.509	91.0	333	0.4	Glaucoma	68.52
82	45.7	4.270	1.796	103.2	335	0.4	Glaucoma	62.82
83	49.3	3.9	2.1	95.9	331.0	0.4	Control	8.05
84	48.7	3.665	2.37	92.6	324	0.4	Control	4.73
85	47.9	3.4	2.0	91.2	324.0	0.4	Control	4.54
86	43.8	2.955	1.70	90.5	347	0.4	Control	25.90
87	45.3	3.5	2.6	97.6	320.0	0.4	Control	4.27
88	45.9	3.0	2.8	96.6	320.0	0.3	Control	0.38
89	45.8	1.9	1.7	91.4	323.0	0.4	Control	17.51
90	45.3	1.5	1.01	90.8	340	0.4	Control	7.28
91	52.0	4.0	1.6	93.9	319.0	0.4	Control	2.84
92	50.5	4.4	1.9	94.9	325.0	0.4	Control	6.06
93	53.8	4.2	2.1	94.7	323.0	0.4	Control	3.36
94	43.4	2.782	1.67	88.6	325	0.4	Control	35.34
95	47.4	5.566	2.22	88.4	331	0.4	Control	71.70
96	43.8	3.394	1.99	87.6	365.0	0.4	Control	64.27
97	43.5	4.9	1.6	93.3	331.0	0.4	Control	22.72
98	44.9	3.4	2.3	99.6	330.0	0.5	Control	87.49
99	47.5	4.3	2.1	99.4	320.0	0.4	Control	32.21
100	45.8	2.138	1.52	93.9	338	0.4	Control	8.02
101	50.0	3.9	1.4	85.2	312.0	0.4	Control	2.28
102	47.2	3.4	1.8	94.6	324.0	0.4	Control	4.71
103	47.6	5.790	3.01	90.3	330	0.4	Control	22.17
104	45.4	4.287	2.11	99.6	315.0	0.4	Control	4.43

105	47.6	5.8	3.2	100.0	317.0	0.4	Control	8.59
106	46.9	3.052	1.95	94.6	341	0.4	Control	13.51
107	46.5	4.4	2.7	91.7	331.0	0.4	Control	13.88
108	44.5	5.057	1.77	87.9	339	0.4	Control	36.63
109	48.6	3.5	2.2	97.4	319.0	0.4	Control	2.92
110	48.0	3.5	1.9	94.1	327.0	0.4	Control	5.78
111	51.8	3.0	2.0	97.6	324.0	0.4	Control	2.28
112	45.9	4.5	3.6	94.4	331.0	0.4	Control	14.25
113	51.4	4.711	2.24	93.8	339	0.4	Control	17.01
114	46.7	4.6	1.6	88.3	315.0	0.4	Control	5.36
115	49.1	4.4	2.5	93.3	310.0	0.4	Control	2.39
116	50.1	4.581	2.46	97.5	345	0.4	Control	24.61
117	43.4	3.7	1.4	95.4	311.0	0.4	Control	22.38
118	43.1	2.4	1.1	97.3	313.0	0.4	Control	14.31
119	37.4	2.6	0.8	102.5	316.0	0.4	Control	29.15
120	40.3	2.7	1.5	95.3	323.0	0.4	Control	6.35
121	42.7	1.7	1.4	93.6	319.0	0.4	Control	2.19
122	45.2	2.6	1.7	95.0	325.0	0.4	Control	4.25
123	41.1	2.5	1.4	90.7	319.0	0.4	Control	4.13
124	44.7	1.7	1.2	95.3	313.0	0.4	Control	1.14
125	42.0	2.2	1.3	94.4	321.0	0.4	Control	3.67
126	44.7	2.1	1.2	95.1	318.0	0.4	Control	2.10
127	42.0	5.6	2.1	94.6	329.0	0.4	Control	29.48
128	44.7	3.7	2.4	91.4	322.0	0.4	Control	6.27
129	44.4	1.6	1.5	103.7	309.0	0.4	Control	5.88
130	42.4	2.6	1.4	94.4	321.0	0.4	Control	4.33
131	43.8	6.2	0.7	94.0	322.0	0.4	Control	23.56

132	42.9	3.3	1.6	100.0	326.0	0.4	Control	7.68
133	45.0	3.7	1.5	99.6	331.0	0.4	Control	10.64
134	45.0	3.1	1.8	93.4	318.0	0.4	Control	3.35
135	37.8	1.5	2.1	103.0	328.0	0.4	Control	5.40
136	43.1	2.8	1.2	95.8	323.0	0.4	Control	5.18
137	41.3	2.9	1.1	91.0	320.0	0.4	Control	5.46
138	43.4	2.5	2.2	99.3	320.0	0.4	Control	3.11
139	45.1	4.0	2.3	90.0	322.0	0.4	Control	7.43
140	43.5	2.5	1.7	95.2	324.0	0.4	Control	4.29
141	43.1	4.8	1.2	94.9	316.0	0.4	Control	8.54
142	42.2	2.5	1.7	94.4	332.0	0.4	Control	9.13
143	43.4	3.6	1.7	90.8	318.0	0.4	Control	5.27
144	42.9	4.1	1.4	88.1	329.0	0.4	Control	15.92
145	45.4	2.9	1.6	92.7	328.0	0.4	Control	6.04
146	39.9	4.1	1.7	92.6	336.0	0.4	Control	29.26
147	42.0	2.8	1.3	95.5	329.0	0.4	Control	45.12
148	46.4	3.6	1.2	91.2	321.0	0.4	Control	5.00
149	34.5	3.7	1.9	98.6	333.0	0.4	Control	30.34
150	38.9	3.2	0.7	96.3	314.0	0.4	Control	5.08
151	42.7	3.2	2.4	95.7	319.0	0.4	Control	4.58
152	46.0	3.4	2.2	87.3	333.0	0.4	Control	11.08
153	45.2	2.5	2.0	91.3	327.0	0.4	Control	4.72
154	44.1	4.0	1.4	94.6	327.0	0.4	Control	11.27
155	38.4	1.8	1.9	97.5	315.0	0.4	Control	2.49
156	41.4	3.2	1.8	87.3	321.0	0.4	Control	6.76
157	39.2	2.5	1.2	95.1	321.0	0.4	Control	5.58
158	43.5	3.0	1.3	91.2	317.0	0.4	Control	3.57

159	41.4	3.5	2.6	100.2	326.0	0.4	Control	9.47
160	43.3	2.7	1.4	89.6	328.0	0.4	Control	7.05
161	43.4	2.6	2.8	90.8	329.0	0.4	Control	6.69
162	44.2	3.9	2.1	94.2	314.0	0.4	Control	4.03
163	44.3	2.3	1.4	94.1	318.0	0.4	Control	2.39
164	42.5	2.1	1.2	88.7	329.0	0.4	Control	6.13

---

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

**Table 6. External validation performance**

---



<b>Dataset</b>	<b>AUC</b>
Dataset 1	0.96
Dataset 2	0.94
Dataset 3	0.95

640

641

642